We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Vivesto AB (VIVE) NPV

Sell:0.29 SEK Buy:0.29 SEK Change: 0.0045 SEK (1.55%)
Market closed |  Prices as at close on 26 April 2024 | Switch to live prices |
Sell:0.29 SEK
Buy:0.29 SEK
Change: 0.0045 SEK (1.55%)
Market closed |  Prices as at close on 26 April 2024 | Switch to live prices |
Sell:0.29 SEK
Buy:0.29 SEK
Change: 0.0045 SEK (1.55%)
Market closed |  Prices as at close on 26 April 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Vivesto AB, formerly Oasmia Pharmaceutical AB is a Swecen-based pharma company that develops new treatment options for patients suffering from difficult-to-treat cancer. The company has a growing portfolio of projects in the clinical phase focused on advanced cancer. Apealea (paclitaxel micellar) is being developed for patients with ovarian cancer through a partnership with Elevar Therapeutics, Inc. Other development programs include Cantrixil, a clinical program in advanced ovarian cancer, and docetaxel micellar, which is being developed for widespread prostate cancer. Vivesto's patented technology platform is developed to improve the water solubility, efficacy and safety of drugs.

Contact details

Address:
Gustav III:s Boulevard 46, 5tr
SOLNA
169 73
Sweden
Telephone:
+46 (18) 505440
Website:
https://www.vivesto.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
VIVE
ISIN:
SE0000722365
Market cap:
155.76 million SEK
Shares in issue:
538.04 million
Sector:
Biotechnology
Exchange:
Stockholm Stock Exchange
Country:
Sweden
Currency:
Swedish Krona
Indices:
n/a

Key personnel

  • Erik Kinnman
    Chief Executive Officer
  • Robert Maiorana
    Acting Chief Financial Officer
  • Kai Wilkinson
    Chief Technology Officer
  • Reinhard Koenig
    Chief Scientific Officer
  • Johanna Rostin
    Chief Regulatory Officer
  • Peter Selin
    Chief Business Officer
  • Daniel Tesfa
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.